JAK-STAT Pathway Deregulation, Sarcoidosis
Conditions
Keywords
Sarcoidosis, JAK/STAT
Brief summary
Recent studies suggest that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis. Further investigations are necessary to identify the most suitable patients to receive treatment targeting this pathway, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines.
Detailed description
The investigators hypothesize that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines. The main objective of this proposal is to evaluate the presence and stage of activation of the JAK/STAT pathway in PBMCs from inactive and active sarcoidosis patients. The second objective will be to determine the role of the JAK/STAT pathway in the formation and maintenance of granulomas and their association with the severity of sarcoidosis and fibrogenesis.
Interventions
OTHERBlood sample
Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS / ERS / WASOG criteria * Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other probable causal factor identified on the usual standard examination at the time of the sample with the need for diagnostic confirmation at the end of the study according to the criteria of the ATS / ERS / WASOG * Sarcoidosis with stage 1 to 4 pulmonary involvement * Patients who had a chest CT scan in the 6 months preceding the sample. Examination carried out as part of routine care
Exclusion criteria
* Pregnancy. * Opposition expressed to participation in the study. * Patients on State Medical Aid.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| JAK/STAT familly numbers protein expression in PBMCs | 1 year after inclusion | Evaluation will be carried out by: \- studying the expression of members of the JAK/STAT pathway, the expression of cytokines and chemokines phagocytosis and macrophage differentiation the expression of cytokines and chemokines |
Countries
France
Contacts
Primary ContactFlorence JENY, MD
Backup ContactValerie BESNARD, PhD
Outcome results
None listed